Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments:
Maximilian Merz Awarded $2.3 Million From the Hector Foundation
Maximilian Merz, MD, mmyeloma specialist, has been
awarded $2.3 million by the Hector Foundation (Hector-Stiftung), a nonprofit institution based in Germany. This funding will support his research on the effects of CAR T cells and bispecific antibodies on the immune system of patients suffering from myeloma. Dr. Merz led the investigation with Kristin Reiche from Leipzig University Medical Center in Germany, and their findings were published in
Cancer Cell.Shelly Anderson Recognized on “2026 Trailblazers in Healthcare” List
Shelly Anderson, MPM, Hospital President, has been
named to City & State New York’s annual “Trailblazers in Healthcare” list for 2026. The recognition highlights influential healthcare leaders in New York, including executives, elected officials, and advocates.
City & State New York is a media organization dedicated to providing in-depth, nonpartisan coverage of local and state politics and policy.
Selwyn Vickers Named Among “The 100 Most Influential CEOs in Oncology 2025” by OncoDaily
Selwyn M. Vickers, MD, FACS, President and CEO, was
named as one of the Most Influential CEOs in Oncology 2025 by OncoDaily. The list honors chief executive officers whose leadership has made a measurable and lasting impact on the global oncology ecosystem, featuring executives from major international cancer institutions as well as leaders of specialized societies and emerging innovators. These executives’ decisions continue to shape the fight against cancer.
Andrea Schietinger Awarded Funding from The Cancer Research Institute
Andrea Schietinger, PhD, cancer immunologist, has been
awarded funding by the Cancer Research Institute (CRI). Dr. Schietinger will work with researchers from Stanford University School of Medicine and the University of Pennsylvania Perelman School of Medicine in the
CRI Discovery Engine, a first-of-its-kind, AI-ready database that captures high-resolution spatial and temporal molecular data showing how immune and cancer cells respond to immunotherapy. Initially focused on melanoma and colorectal cancer, the Discovery Engine aims to accelerate the discovery of new immunotherapy strategies and create a shared, living resource that enables researchers to understand why treatments work, fail, or can be improved.
MSK Named One of America’s Top 100 Charities by Forbes
MSK was recognized by Forbes as one of America’s Top 100 Charities. This recognition reflects MSK’s continued commitment to deliver world-class patient care. The top 100 ranking was based on private contributions in each charity’s last reported fiscal year.
